skip to main content

AF Anticoagulation in Liver Disease — EECC MCQ

Instant feedback + full explanation. One question, done properly.

HardArrhythmia & ElectrophysiologyAF Anticoagulation in Liver DiseaseEECC

A 70-year-old woman with permanent AF, Child-Pugh B liver cirrhosis (score 8), and a CHA₂DS₂-VA score of 4 requires anticoagulation for stroke prevention. Her platelet count is 85 × 10⁹/L and INR is 1.6 (baseline, not anticoagulated). Which anticoagulation approach is most appropriate?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Specialist-guided cautious anticoagulation

Explanation lettering: C = shown as A · E = shown as B · B = shown as C · A = shown as E

Anticoagulation in AF patients with liver cirrhosis is challenging. DOACs are generally not recommended in Child-Pugh C cirrhosis, but may be used with caution in Child-Pugh A/B with appropriate dose adjustments and monitoring. The 2024 ESC AF Guidelines note the limited evidence in this population. Edoxaban 30 mg (reduced dose for hepatic impairment) and apixaban (with appropriate dose adjustment for concomitant factors) have some emerging safety data in compensated cirrhosis. Warfarin is problematic as the baseline INR is already elevated, making therapeutic monitoring unreliable. Antiplatelet agents alone are insufficient for stroke prevention in high-risk AF. Specialist multidisciplinary input (cardiology + hepatology) is essential.

Reference: ESC (2024): Guidelines for the Management of Atrial Fibrillation: https://bnf.nice.org.uk/drugs/warfarin-sodium/